Is your siRNA "silent" again? No, silence is useless! A must-read guide for researchers to avoid the pitfalls of oligonucleic acid testing!

Release time:2026-06-26

If you've also been "tormented" by oligonucleic acids in the lab—after transfection, large cell patches float up, fluorescence fills the field but no protein knocks down, only one of the two siRNAs has a phenotype—don't rush to doubt your life; most likely, you've fallen into some classic trap. Today's article is pure practical content, covering all the most frequently asked small nucleic acid questions in the research community.

Recognize your opponent: Which type of oligonucleic acid are you actually using?

Many junior students entering the lab for the first time instinctively think it's siRNA when they hear the words "oligonucleotide." In fact, this family has far more members than you might think. Using the wrong tools naturally causes the phenotypes to match.

siRNA (small interfering RNA):

Double-stranded, after entering the cell, the antisense strand is loaded onto the RISC complex to degrade the target mRNA by shearing. Suitable for short-term gene silencing, chemical synthesis, effective 24–72 hours after transfection, and lasting several days.

shRNA (short hairpin RNA):

Transcription is done within the nucleus via plasmids or viral vectors, and after processing, a double-stranded siRNA-like structure is generated. Its advantage is the ability to build stable, silent cell lines, with slightly slower but longer-lasting onset.

miRNA mimics & inhibitors：

Replicating endogenous miRNA function (mimics, double-stranded) or sealing endogenous miRNA (inhibitors, single-stranded, usually with high-affinity modifications). Essential for studying miRNA functions.

ASO (Antisense Oligonucleotide):

Single-stranded DNA analogs that cut target RNA via RNase H or are used to regulate variable splicing. Suitable for targets that are difficult for RNAi to conquer.

Aptamer (Nucleic Acid Aptamer):

Single-stranded oligonucleotides bind to three-dimensional structures or small molecules, serving as nucleic acid versions of antibodies. They can be used as inhibitors, targeted delivery vectors, or live cell probes.

Core selection tips:

To quickly → siRNA in the short term
Long-term stability of → shRNA viral vectors is required
Block endogenous miRNA → inhibitors
Target the protein → aptamer

Design is king: How a good siRNA is forged

Once you get the gene sequence, just pick a random segment of 21Nt and throw it into synthesis? That silence efficiency is most likely mystical.

1. How to choose a target

Priority is given to the CDS area, starting from 50–100 nt downstream of the initial codon.
Avoid 5′-UTR and 3′-UTR unless you specifically want to study UTR functionality.
The length is usually 19+2 (19 bp double-stranded region, two protruding bases at the 3′ end, commonly dTdT or UU).

2. Sequence preference

The 5′ end of the justice chain favors A/U, which helps the antisense chain be selected by RISC.
The antisense strand seed region (positions 2–7) avoids high homologous to the miRNA seed region, which is the main source of off-target.
A GC content of 35%–52% in the whole sequence is ideal.
Avoid consecutive repeats (> 4 identical bases), palindromics, and immune-stimulatory motifs (such as GUCCUUCAA).

3. Specificity verification

BLAST is your bottom line. Ensure that the antisense strand seed region does not have a significant continuous match with the non-target transcript. Cross-validation is then conducted using online tools such as Dharmacon siDESIGN, siDirect 2.0, and IDT.

4. The two main culprits behind the off-target effect

miRNA-like off-target: The seed region misbinds to other mRNA's 3′-UTR, inhibiting translation.
Chain of justice mistakenly enters RISC: Chain of justice takes the lead, silencing other genes.

Solution:

1. Utilizes thermodynamic asymmetry to make the 5′ end of the antisense strand easier to unchain.

2. Introducing 2′-OMe modifications into the antisense strand seed region significantly reduces off-target behavior.

3. Design at least two valid siRNAs at the same target; only if the phenotypes are consistent does it count.

5. How to choose chemical modifications

For routine cell experiments, unmodified siRNA is sufficient. But when encountering cells that are difficult to transfect or experiments in vivo, modification can determine life or death:

2′-OMe: Anti-nuclease, immunogenicity, commonly used in seed areas.
2′-F: Enhances affinity for combination.
Thiophosphate (PS): Linked bond modification, anti-nuclease activity.
LNA: Greatly enhances affinity, standard for miRNA inhibitors.
Cholesterol/GalNAc conjugation: supports targeted delivery in the body.

On the labbed: those details that will make you break down

1. Dissolution and preservation

Briefly centrifuge before opening the lid, and all operations are performed in an RNase-free environment. Prepare 100 μM mother liquor with DEPC water or RNase-free water, aliquot, and store away from light at -20°C or -80°C. Repeated freeze-thaw cycles of 3–5 times are stable, but repackaging is the optimal solution. Fluorescent labeling must be strictly protected from light.

2. The transfection efficiency is so low it's almost frustrating

First, check these points:

Cell status: Log growth phase, convergence maintained at 60%–80% during transfection.
Transfection reagent matching: Reagents suitable for different cell lines vary greatly; a round of reagent screening is necessary if necessary.
Ratio: 24-well plates commonly use 1–3 μL transfection reagent corresponding to 10–50 pmol siRNA, requiring self-gradient optimization.
Serum-free environment: Be sure to use serum-free media such as Opti-MEM when preparing complexes.
Electroporation as a backup: Hard-to-transfect cells can be directly treated with systems like Lonza Nucleofector.

It is recommended to first use siRNA labeled with FAM/Cy3 to objectively assess transfection efficiency through microscopy or flow cytometry, rather than relying on intuition.

3. A set of non-negotiable comparisons

Untreated: Cells that are completely untreated, excluding the effects of the procedure.
Mock (adding only transfection reagents): excludes reagent toxicity.
Negative control (scrambled/non-targeting): a baseline that normalizes all parameters.
Positive controls (such as GAPDH, Lamin A/C): Demonstrate the effectiveness of transfection and silencing systems themselves.
Second target: siRNA: the best alternative for biological duplication.

All controls had to be run at the same final concentration; otherwise, comparisons were meaningless.

4. When should the silence efficiency be measured?

mRNA (qPCR): 24–48 hours is a common window, with some cells as early as 6 hours. The primer should try to cross exons as much as possible.
Western blot: 48–72 hours or longer, depending on the half-life of the target protein. Long-half-life proteins may even require 96 hours or secondary transfection.

Ideal silence is achieved when mRNA decreases by ≥70% and proteins decrease simultaneously. If mRNA lowers protein but does not, it suggests possible translation off-target or extremely stable proteins.

5. If the cells die, who's to blame?

Let's look at the mock group first. If the mock also dies out, it's a reagent issue.
If the mock is alive and well, siRNA itself may be at play: some sequences activate the TLR7/8 immune pathway, which can be verified by detecting IFN-β, OAS1, and others. At this point, switching to 2′-OMe modification or reducing siRNA concentration (at a 1–50 nM gradient) often saves the product.

Ultimately, toxicity was confirmed as an on-target: rescue experiment. After silencing, exogenous expression of a target gene version that cannot be recognized by the siRNA indicates phenotypic restoration specificity, while failure to recover may result in toxicity of the sequence itself.

Advanced gameplay: miRNA, in vivo experiments and screening

1. The particularities of miRNA mimics and inhibitors

Mimics are double-stranded and must be processed by Dicer. The choice of positive and negative strands is important; you cannot arbitrarily synthesize a mature miRNA sequence.
Inhibitors are high-concentration single-stranded (30–100 nM) with large amounts of LNA or 2′-OMe modifications, which tightly bind and seal endogenous miRNAs.
The control should be matched accordingly: scrambled mimics, negative inhibitor (a single-stranded random sequence with the same modification).
Efficacy validation can be achieved using target gene qPCR or dual luciferase reporting systems.

2. Deliver the three-piece set inside the body

If siRNA is injected into animals, the half-life of bare RNA is extremely short. Mainstream Strategy:

Chemical modifications: 2′-F, 2′-OMe, PS fully reinforced frameworks.
Binding targeting: GalNAc-siRNA targets the liver, while cholesterol-siRNA enables local/systemic delivery.
Nanocarriers: LNP or polymer encapsulation protection.
Viral vector shRNA: AAV, lentivirus, combined with tissue-specific promoter.

3. How do you play whole-genome screening?

Synthesizing siRNA array libraries or pooling shRNA libraries, microplate reverse transfection combined with phenotypic (proliferation, fluorescence) readings, followed by NGS analysis for enrichment and consumption. Candidates selected must be re-validated with independent siRNA to reduce false positives caused by off-target behavior.

Data doesn't lie: verification and troubleshooting

1. Can a phenotype of siRNA be trusted?

Only then should I consider further development, after at least two independent siRNAs can replicate the phenotype. The gold standard is always the rescue experiment: inserting synonymous mutants of the target gene or cDNA with siRNA targets removed, and restoring the phenotype—this is the ultimate verification.

2. Fluorescent light fills the field of view but no knock is lowered—what's going on?

Fluorescence only proves that nucleic acids have entered the cell, but it may not have entered the cytoplasm. siRNA is likely confined within endosomes/lysosomes. Chloroquine or Blafidazin A can help determine the presence of endosomal escape disorder. Additionally, be careful not to interfere with the fluorescent marking position to prevent RISC loading; typically, marking the 5′ end of the justice chain is safer.

3. Aptamer is more than just a concept

Aptamer identifies target molecules through 3D conformations and has been applied to:

Protein function blockade: similar to inhibitors.
Targeted delivery: Precisely delivering siRNA or drugs to specific cells.
Live cell imaging: Identifies surface markers and mildly substitutes for antibodies.

The aptamers selected by SELEX technology are becoming hidden treasures in the oligonucleotide toolbox.

One-stop platform: the fast track from "concept" to "candidate."

GentleGen's one-stop service platform is not simply a piece of various services, but deeply integrates core capabilities such as target evaluation, sequence design, synthetic purification, active screening, and sequence modification & conjugation, truly achieving a "just think and get" R&D experience.

For every scientist striving forward on the path of nucleic acid drug development, choosing a reliable partner often means half the battle. Next time you feel troubled by siRNA/ASO synthesis and screening, perhaps remember: GentleGen's one-stop platform has already paved a "highway" to your destination. For detailed information about related services, please send an email to marketing@gentlegen.com.

Contact Sales

Contact Sales Assistant

Contact PM